Guideline topic: Asthma 2018-19 Update

**General comments**
This update was based on 12 key questions covering the following topics: monitoring, self-management, non-pharmacological and pharmacological management, and acute asthma.
An additional question on vitamin D supplementation was added during the guideline development process.

**Search coverage**

**Systematic reviews**
The systematic review search was conducted using the generic stem search strategy outlined below in conjunction with the SIGN systematic review filter. A single search for systematic reviews was carried out for Key Questions 1-12. The results were then sifted for each individual question.
Key Question 13 was searched separately as it was added later (no date limit, date searched 23/05/18).

<table>
<thead>
<tr>
<th>Databases covered: Medline, Embase, Cochrane Library, Cinahl</th>
<th>Dates covered: 2012-01/03/2018 (KQ1-12)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total hits:</strong> 2817 (KQ1-12)</td>
<td><strong>Sifted result:</strong> see Scope of Searches below</td>
</tr>
<tr>
<td>125 (KQ13)</td>
<td><strong>Papers requested:</strong> see Scope of Searches below</td>
</tr>
</tbody>
</table>

**RCTs**

| Databases covered: Medline, Embase, Cochrane Library, Cinahl | Dates covered: (with variations depending on topic; see Scope of Searches below) |

**Observational studies/ Searches without filter**

| Databases covered: Medline, Embase, Cochrane Library, Cinahl | Dates covered: (with variations depending on topic; see Scope of Searches below) |

**Search strategies**
The following are listings of the main Medline strategies used for this guideline. All conventions and symbols are from the Ovid implementation of Medline. Strategies used in other databases were substantially the same, though different terminology may have been used to take account of different thesauri used in non-Medline databases.
Search filters were added to identify studies of a particular type (systematic review, RCT etc.) Listings of the search filters used by SIGN can be found on the SIGN Web site.

**Generic Stem:**
1. exp Asthma/
2. asthma*.tw.
3. 1 or 2
### Scope of searches for SRs, RCTs, and no filter (NOF) searches

<table>
<thead>
<tr>
<th>KQ</th>
<th>Type of studies</th>
<th>Date range</th>
<th>Initial recall</th>
<th>Sifted result</th>
<th>Requested</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>SR</td>
<td>2012-2018</td>
<td>2817</td>
<td>19</td>
<td>17</td>
</tr>
<tr>
<td>1</td>
<td>NOF</td>
<td>2014-2018</td>
<td>1030</td>
<td>18</td>
<td>6</td>
</tr>
<tr>
<td>2</td>
<td>SR</td>
<td>2012-2018</td>
<td>2817</td>
<td>17</td>
<td>17</td>
</tr>
<tr>
<td>2</td>
<td>NOF</td>
<td>No date limit</td>
<td>465</td>
<td>33</td>
<td>29</td>
</tr>
<tr>
<td>3</td>
<td>SR</td>
<td>2012-2018</td>
<td>2817</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>NOF</td>
<td>No date limit</td>
<td>965</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>4</td>
<td>SR</td>
<td>2012-2018</td>
<td>2817</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>4</td>
<td>NOF</td>
<td>2014-2018</td>
<td>324</td>
<td>26</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>SR</td>
<td>2012-2018</td>
<td>2817</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>5</td>
<td>RCT</td>
<td>2013-2018</td>
<td>298</td>
<td>20</td>
<td>13</td>
</tr>
<tr>
<td>6</td>
<td>SR</td>
<td>2015-2018</td>
<td>2817 (for 2012-18)</td>
<td>24</td>
<td>22</td>
</tr>
<tr>
<td>6</td>
<td>RCT*</td>
<td>2014-2018</td>
<td>364</td>
<td>25</td>
<td>12</td>
</tr>
<tr>
<td>7</td>
<td>SR</td>
<td>2012-2018</td>
<td>2817</td>
<td>19</td>
<td>16</td>
</tr>
<tr>
<td>8</td>
<td>SR</td>
<td>2012-2018</td>
<td>2817</td>
<td>22</td>
<td>19</td>
</tr>
<tr>
<td>9</td>
<td>SR</td>
<td>2012-2018</td>
<td>2817</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>10</td>
<td>SR</td>
<td>2012-2018</td>
<td>2817</td>
<td>21</td>
<td>21</td>
</tr>
<tr>
<td>11</td>
<td>SR</td>
<td>2012-2018</td>
<td>2817</td>
<td>30</td>
<td>27</td>
</tr>
<tr>
<td>12</td>
<td>SR</td>
<td>2012-2018</td>
<td>2817</td>
<td>26</td>
<td>25</td>
</tr>
<tr>
<td>13</td>
<td>SR</td>
<td>No date limit</td>
<td>125</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>13</td>
<td>RCT</td>
<td>2016-2018</td>
<td>164</td>
<td>15</td>
<td>7</td>
</tr>
</tbody>
</table>

*For KQ6 the results of update searches for 5 Cochrane Reviews were provided via the Cochrane Airways Group. These update searches were sifted to identify any relevant RCTs.

**Medline Search strategies used for specific key questions (combined with generic stem search strategy):**

**KQ 1 (monitoring current asthma control)**

1. symptom score*.tw.
2. control score*.tw.
3. exp Respiratory Function Tests/
4. lung function test*.tw.
5. Bronchial Hyperreactivity/
6. bronchial reactivity.tw.
8. airway responsiveness.tw.
9. Breath Tests/
10. exhaled condensate*.tw.
11. breath condensate*.tw.
12. EBC.tw.
13. SPUTUM/
14. sputum.tw.
15. Eosinophils/
16. eosinophil*.tw.
17. Periostin.tw.
18. marker*.tw.
19. biomark*.tw.
20. Biomarkers/
21. Monitoring, Physiologic/
22. monitor*.tw.
23. or/1-20
24. or/21-22
25. 23 and 24

**KQ 2 (prediction of future loss of control and/or future risk of attacks)**
1. exp Asthma/
2. asthma.tw.
3. 1 or 2
4. (predict* adj5 attack*).tw.
5. (predict* adj5 exacerbation*).tw.
6. 4 or 5
7. 3 and 6
8. loss of control.tw.
9. predict*.tw.
10. 3 and 8

KQ 3 (increasing the dose of ICS or adding an LTRA as part of self-management)

1. Patient Participation/
2. self care/ or self-management/
3. Self Administration/
4. self care.tw.
5. self management.tw.
6. {self adj3 administer*}.tw.
7. {{patient* or parent* or caregiver* or carer*} adj3 (initiat* or suggest* or instigat* or originat* or request* or propose* or encourage* or advocate*)}.tw.
8. or/1-7
10. Inhaled glucocorticoid*.tw.
11. ICS.tw.
12. Beclomethasone/
14. Budesonide/
15. Budesonide.tw.
16. Flunisolide.tw.
17. Fluticasone/
18. Fluticasone.tw.
19. Mometasone Furoate/
20. Mometasone.tw.
21. Triamcinolone Acetonide/
22. Triamcinolone.tw.
23. Leukotriene Antagonists/
24. Leukotriene receptor antagonist*.tw.
25. LTRA*.tw.
27. zafirlukast.tw.
28. or/9-27
29. 8 and 28

KQ 4 (interventions (avoidance or reduction of exposure to environmental factors) in the home/school/outdoor environment)

1. exp Allergens/
2. allergen*.tw.
3. exp Environmental Exposure/
4. {environmental adj5 exposure*}.tw.
5. {environmental adj5 factor*}.tw.
6. IRRITANTS/
7. irritant*.tw.
8. trigger*.tw.
9. exp Mites/
10. dust mite*.tw.
KQ 5 (breathing training)

1. exp Breathing Exercises/
2. Respiratory Therapy/
3. (Breath* adj5 (exercis* or train* or re-train* or technique* or educat* or re-educat* or coach* or adapt*)).tw.

4. (Breath* adj5 (physiotherap* or physical therapy or respiratory therapy)).tw.
5. (breath* adj5 diaphragm*).tw.
6. (breath* adj5 control*).tw.
7. (Lung* adj5 (exercis* or train* or re-train* or technique* or educat* or re-educat* or coach* or adapt*)).tw.
8. (respiratory muscle$ adj5 (exercis* or train* or re-train* or technique* or educat* or re-educat* or coach* or adapt*)).tw.
9. buteyko.tw.
10. (Yoga or yogic).tw.
KQ07 In people with asthma whose symptoms are not adequately controlled by low-dose (>12 years) or very low-dose (<5, 5-12 years) ICS plus a LABA, is adding an LTRA, LAMA, theophylline or slow-release B2-agonist tablets, more effective than increasing the dose of ICS at reducing asthma attacks, improving symptoms, reducing side effects, improving treatment adherence or improving pulmonary/lung function?

1. inhaled corticosteroids.mp.
2. ICS.mp.
3. inhaled steroids.mp.
4. LTRA.mp.
5. *Leukotriene Antagonists/
6. leukotriene receptor antagonists.mp.
7. montelukast.mp.
8. zafirlukast.mp
9. receptors leukotriene. or *Receptors, Leukotriene/
10. long acting bronchodilators.mp.
11. *Bronchodilator Agents/
12. formoterol.mp. or *Formoterol Fumarate
13. Salmeterol.mp. or *Salmeterol Xinafoate/
14. theophyllines.mp. or *Theophylline/
15. long acting muscarinic antagonist.mp
16. *Muscarinic Antagonists/
17. slow acting beta2 agonist.mp
18. *Adrenergic beta-Agonists/ or long-acting Beta-2 Agonists.mp. or *Adrenergic beta-2 Receptor Agonists/
19. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. 1 or 2 or 3
21. 19 and 20

KQ08 In people with asthma who are not adequately controlled on high-dose ICS plus LABA or on oral corticosteroids, does addition of monoclonal antibodies (eg, omalizumab, mepolizumab, reslizumab) reduce use of oral steroids, unscheduled care, side-effects, or improve symptoms, treatment adherence or lung function?

1. inhaled corticosteroids.mp.
2. ICS.mp.
3. inhaled steroids.mp.
4. long acting bronchodilators.mp
5. *Bronchodilator Agents
6. formoterol.mp. or *Formoterol Fumarate/
7. Salmeterol.mp. or *Salmeterol Xinafoate
8. corticosteroids.mp. or *Adrenal Cortex Hormones
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. monoclonal antibodies.mp. or *Antibodies, Monoclonal/
11. omalizumab.mp. or *Omalizumab/
12. Antibodies, Monoclonal, Humanized/ or mepolizumab.mp.
13. reslizumab.mp
14. 10 or 11 or 12 or 13
15. 9 and 14

KQ09. In people with asthma who are not adequately controlled on high-dose ICS plus a LABA or oral corticosteroids, does addition of bronchial thermoplasty reduce use of oral steroids, unscheduled care, side-effects, or improve symptoms, treatment adherence or lung function??

1. inhaled corticosteroids.mp.
2. ICS.mp.
3. inhaled steroids.mp.
4. long acting bronchodilators.mp
5. *Bronchodilator Agents
6. formoterol.mp. or *Formoterol Fumarate/
7. Salmeterol.mp. or *Salmeterol Xinafoate
8. corticosteroids.mp. or *Adrenal Cortex Hormones
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. bronchial thermoplasty.mp. or *Bronchial Thermoplasty/
11. 9 and 10

**KQ10. In people with asthma who are poly- or mono-sensitised, is sublingual immunotherapy compared to standard therapy effective at reducing asthma attacks, improving asthma control, improving treatment adherence or improving lung function?**

1. sublingual therapy.mp.
2. sublingual immunotherapy.mp. or *Sublingual Immunotherapy/
3. 1 or 2

**KQ11. What interventions in the home or workplace/school improve adherence with asthma treatments?**

1. inhaler adherence.mp. or *Administration, Inhalation/
2. *Time Factors/ or timers.mp.
3. *Clinical Alarms/ or alarms.mp.
4. directly observed therapy.mp. or *Directly Observed Therapy/
5. patient compliance.mp. or *Patient Compliance/
6. 2 or 3 or 4 or 5
7. 1 and 6

**KQ12. In the immediate treatment of people with life-threatening or near-fatal asthma, does extracorporeal membrane oxygenation (ECMO) or other potentially life-saving therapies, compared to usual care, improve patient survival or other outcomes?**

1. *Extracorporeal Membrane Oxygenation/ or ECMO.mp.
2. ketamine.mp. or *Ketamine/
3. rescue therapies.mp.
4. or/1-3

**KQ 13 (vitamin D supplementation)**

1. exp ASTHMA/
2. asthma.tw.
3. 1 or 2
4. exp Vitamin D/
5. exp Vitamin D Deficiency/
6. vitamin d.tw.
7. or/4-6
8. 3 and 7